Colchicine for Intracranial Hemorrhage
(CoVasc-ICH Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to test if colchicine, an anti-inflammatory medication, can safely prevent heart and brain damage in patients who have had a stroke caused by brain bleeding. Colchicine has been studied for its potential to reduce the incidence of postoperative atrial fibrillation and has shown some effectiveness in reducing inflammation.
Who Is on the Research Team?
Aristeidis Katsanos, MD
Principal Investigator
Population Health Research Institute
Ashkan Shoamanesh, MD
Principal Investigator
Population Health Research Institute
Are You a Good Fit for This Trial?
This trial is for individuals who've had a spontaneous brain bleed within the last 48 hours and can consent to participate. It's not for those with ICH due to trauma, liver issues, or on certain drugs that interact badly with colchicine. Pregnant women and people unlikely to follow the study plan or live less than six months are also excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive oral colchicine 0.5mg or placebo once daily
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Colchicine
Colchicine is already approved in United States for the following indications:
- Gout
- Familial Mediterranean Fever
Find a Clinic Near You
Who Is Running the Clinical Trial?
Population Health Research Institute
Lead Sponsor